Akebia Therapeutics, Inc. (AKBA)
0.9204
+0.04
(+4.76%)
USD |
NASDAQ |
Aug 31, 12:51
Akebia Therapeutics Free Cash Flow : 40.26M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.26M |
| March 31, 2026 | 60.04M |
| December 31, 2025 | 67.70M |
| September 30, 2025 | 32.17M |
| June 30, 2025 | -2.551M |
| March 31, 2025 | -34.86M |
| December 31, 2024 | -40.69M |
| September 30, 2024 | -38.53M |
| June 30, 2024 | -39.00M |
| March 31, 2024 | -25.28M |
| December 31, 2023 | -23.38M |
| September 30, 2023 | -75.76M |
| June 30, 2023 | -34.78M |
| March 31, 2023 | -69.07M |
| December 31, 2022 | -73.27M |
| September 30, 2022 | -81.40M |
| June 30, 2022 | -171.47M |
| March 31, 2022 | -203.95M |
| December 31, 2021 | -253.02M |
| September 30, 2021 | -221.32M |
| June 30, 2021 | -192.24M |
| March 31, 2021 | -91.92M |
| December 31, 2020 | -110.70M |
| September 30, 2020 | -171.96M |
| June 30, 2020 | -136.31M |
| Date | Value |
|---|---|
| March 31, 2020 | -213.83M |
| December 31, 2019 | -264.10M |
| September 30, 2019 | -246.27M |
| June 30, 2019 | -267.50M |
| March 31, 2019 | -218.33M |
| December 31, 2018 | -99.10M |
| September 30, 2018 | -41.40M |
| June 30, 2018 | -83.84M |
| March 31, 2018 | -68.45M |
| December 31, 2017 | -57.78M |
| September 30, 2017 | 54.67M |
| June 30, 2017 | 80.38M |
| March 31, 2017 | 27.96M |
| December 31, 2016 | 55.24M |
| September 30, 2016 | -63.36M |
| June 30, 2016 | -43.01M |
| March 31, 2016 | -26.95M |
| December 31, 2015 | -52.82M |
| September 30, 2015 | -39.06M |
| June 30, 2015 | -35.56M |
| March 31, 2015 | -30.11M |
| December 31, 2014 | -27.71M |
| September 30, 2014 | -23.41M |
| June 30, 2014 | -20.71M |
| March 31, 2014 | -15.97M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Emergent BioSolutions, Inc. | 85.90M |
| Exelixis, Inc. | 1.172B |
| ADMA Biologics, Inc. | 116.22M |
| Arcutis Biotherapeutics, Inc. | 39.15M |
| Relay Therapeutics, Inc. | -212.20M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 3.525M |
| Cash from Investing (Quarterly) | -4.079M |
| Cash from Financing (Quarterly) | -6.538M |
| Free Cash Flow Per Share (Quarterly) | 0.0091 |
| Free Cash Flow to Equity (Quarterly) | 9.555M |
| Free Cash Flow to Firm (Quarterly) | 5.541M |
| Free Cash Flow Yield | 16.26% |